Friday November 26, 2021

SAB Member Prof. Gerding interviewed by Equity Development

Professor Dale Gerding, a world leader in C. difficile infections and a member of the Destiny Pharma Scientific Advisory Board recently spoke to Equity Development about the significant problem of […]

Wednesday November 24, 2021

Destiny Pharma highlighted in WH Ireland analyst note

Destiny Pharma is pleased to be highlighted in an analyst note from WH Ireland titled, “WHI Sector Comment: Strategic themes in healthcare: an AIM perspective“. A copy of the report […]

Thursday November 4, 2021

SAB Member Prof. Gerding is Keynote at C.diff Conference

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma’s SAB Member Professor Dale Gerding is Keynote Speaker at C. diff. International Conference Brighton, United Kingdom – 4th November 2021 […]